Prospective PCSK9 inhibitor (unspecified in snippet)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Prospective PCSK9 inhibitor (unspecified in snippet), covering 2020-07-15 to 2020-07-15. Get the full timeline:
Most recent: Clinical Trial Update: Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders [Phase 3]